Point72 Asset Management L.P. boosted its position in shares of DBV TECHNOLOGIE/S (NASDAQ:DBVT) by 142.9% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 417,064 shares of the company’s stock after purchasing an additional 245,364 shares during the quarter. Point72 Asset Management L.P. owned about 0.46% of DBV TECHNOLOGIE/S worth $3,587,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in DBVT. FNY Investment Advisers LLC purchased a new position in DBV TECHNOLOGIE/S in the second quarter worth about $102,000. LeJeune Puetz Investment Counsel LLC purchased a new stake in shares of DBV TECHNOLOGIE/S during the second quarter valued at $108,000. Cubist Systematic Strategies LLC boosted its position in shares of DBV TECHNOLOGIE/S by 10.2% during the second quarter. Cubist Systematic Strategies LLC now owns 13,284 shares of the company’s stock valued at $109,000 after buying an additional 1,229 shares during the last quarter. Aperio Group LLC purchased a new stake in shares of DBV TECHNOLOGIE/S during the second quarter valued at $152,000. Finally, Jane Street Group LLC bought a new stake in DBV TECHNOLOGIE/S in the 2nd quarter worth about $213,000. Institutional investors and hedge funds own 32.61% of the company’s stock.
DBV TECHNOLOGIE/S stock opened at $7.71 on Tuesday. The stock has a market cap of $712.00 million, a PE ratio of -2.27 and a beta of 1.79. The company has a debt-to-equity ratio of 0.19, a quick ratio of 2.96 and a current ratio of 3.00. DBV TECHNOLOGIE/S has a one year low of $3.60 and a one year high of $16.19. The stock has a fifty day moving average of $7.42 and a 200 day moving average of $8.74.
DBV TECHNOLOGIE/S Company Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
Read More: Leveraged Buyout (LBO) Explained
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.